Bioluminescence Ventures makes it official with $477M in assets for early-stage biotech companies
While the name Bioluminescence Ventures has emerged as an investor in various biotech funding announcements since at least last May, the venture firm officially emerged from stealth on Wednesday, unveiling $477 million in assets.
Led by Kouki Harasaki, a former senior partner at Andreessen Horowitz, Bioluminescence has already put money into early-stage biotechs in Massachusetts like Takeda-backed cell therapy startup Ensoma, neuro-focused Nido Biosciences, immunotherapy developer Surge Therapeutics, and the California-based clinical-stage genetic medicines company ReCode Therapeutics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.